Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Advancing Pathway Analysis With Custom Luciferase Reporters

Part # PS139


Matthew Robers, Brock Binkowski, Natasha Karassina, Pete Stecha, Jey Cheng, Jennifer Wilkinson, Aileen Paguio, Chris Eggers, Braedy Butler, Frank Fan and Mei Cong
Promega Corporation; 2800 Wood Hollow Road, Madison WI 53711

To enable investigation of key cellular signaling pathways, Promega has developed a portfolio of bioluminescent reporter gene assays using Firefly and Renilla luciferases. In combination with best-in-class luciferase detection reagents, these genetic reporter systems enable interrogation of important cellular responses involved in cancer, inflammation and CNS disease. To address specialized customer needs in our industrial and research markets, Promega has a new custom assay service team dedicated to applying these enabling technologies through strategic external research collaborations. The performance of this technology portfolio is presented, including novel applications of luciferase reporters to interrogation of cytokine, stress and toxicity pathway responses.

Printed in USA.